2-苄氧基-5-溴吡啶 | 83664-33-9

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-苄氧基-5-溴吡啶
• 中文别名: 2-苄氧基-5-溴吡啶,95%
• 英文名称: 2-(benzyloxy)-5-bromopyridine
• 英文别名: (5-bromo-2-(phenylmethoxy)-pyridine)；2-Benzyloxy-5-bromopyridine；5-bromo-2-phenylmethoxypyridine
• CAS: 83664-33-9
• 化学式: C₁₂H₁₀BrNO
• 分子量: 264.121
• InChiKey: LXKTVNFZAFTUNZ-UHFFFAOYSA-N

物化性质

• 熔点：
  45-48°C
• 沸点：
  178-178.5 °C(Press: 14 Torr)
• 密度：
  1.438±0.06 g/cm3(Predicted)
• 稳定性/保质期：
  按规定使用和贮存的不会分解，避氧化物。

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  请将药品存放在密闭、阴凉、干燥的地方。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
2-Benzyloxy-5-bromopyridine
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
2-Benzyloxy-5-bromopyridine
Ingredient name:
CAS number: 83664-33-9

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C12H10BrNO
Molecular weight: 264.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-苄氧基-5-溴吡啶 在 高氯酸四乙基铵 、 三乙胺 作用下， 以 乙醇 、 二甲基亚砜 为溶剂， 反应 20.0h， 以92%的产率得到2-(苄氧基)吡啶
  参考文献：
  名称：

  A facile and versatile electro-reductive system for hydrodefunctionalization under ambient conditions

  摘要：

  描述了一种使用三乙胺作为牺牲还原剂的简便电还原去功能化系统，通过简单地改变反应溶剂，可以方便地切换还原的选择性和能力。

  DOI：

  10.1039/d1gc00317h
• 作为产物：
  描述：

  2,5-二溴吡啶 在 sodium hydride 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 3.5h， 生成 2-苄氧基-5-溴吡啶
  参考文献：
  名称：

  PYRIMIDINE COMPOUND AND MEDICINAL COMPOSITION THEREOF

  摘要：

  公开号：

  EP1439175B1

文献信息

• Synthesis of Amido-N-imidazolium Salts and their Applications as Ligands in Suzuki-Miyaura Reactions: Coupling of Hetero- aromatic Halides and the Synthesis of Milrinone and Irbesartan
  作者：Manian Rajesh Kumar、Kyungho Park、Sunwoo Lee

  DOI：10.1002/adsc.201000592

  日期：2010.12.17

  catalytic system based on palladium-amido-N-heterocyclic carbenes for Suzuki–Miyaura coupling reactions of heteroaryl bromides is described. A variety of sterically bulky, amido-N-imidazolium salts were synthesized in high yields from the corresponding anilines. This catalytic system effectively promoted Suzuki–Miyaura couplings of heteroaryl bromides and chlorides with a range of boronic acids to

  描述了基于钯-酰胺基-N-杂环卡宾的Suzuki-Miyaura杂芳基溴化物偶联反应的新催化体系。从相应的苯胺以高收率合成了各种空间庞大的酰胺基-N-咪唑鎓盐。该催化体系有效地促进了杂芳基溴化物和氯化物与一系列硼酸的Suzuki-Miyaura偶联，从而以高收率得到了相应的芳基化合物。随着取代基空间位阻的增加，产率增加。特别是，1-（2,6-二异丙基）-3- ñ - （2,4,6-三-叔-butylphenylacetamido）咪唑鎓溴化物（4BC）在2-溴吡啶和苯基硼酸的偶联反应中显示出850,000 TON。此外，药物化合物如米力农和厄贝沙坦是通过Suzuki-Miyaura偶联，使用体积庞大的酰胺基-N-咪唑鎓盐（4bc）作为配体合成的。
• [EN] SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE<br/>[FR] INHIBITEURS À PETITE MOLÉCULE DE KINASE INDUISANT NF-KB
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2020239999A1

  公开（公告）日：2020-12-03

  The present invention relates to compounds that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are envisaged to be useful for preventing or treating diseases such as cancer (such as B-cell malignancies including leukemias, lymphomas and myeloma), inflammatory disorders, autoimmune disorders, immunodermatologic disorders such as palmoplantar pustulosis and hidradenitis suppurativa, and metabolic disorders such as obesity and diabetes.

  本发明涉及抑制NIK的化合物，以及包含这些化合物的药物组合物和使用方法。这些化合物和药物组合物预期能用于预防或治疗癌症（如包括白血病、淋巴瘤和多发性骨髓瘤的B细胞恶性肿瘤）、炎症性疾病、自身免疫疾病、免疫皮肤病学疾病（如掌跖脓疱病和化脓性汗腺炎）以及代谢紊乱疾病（如肥胖和糖尿病）。
• 1-biaryl-1,8-naphthyridin-4-one phosphodiesterase-4 inhibitors
  申请人：——

  公开号：US20030096829A1

  公开（公告）日：2003-05-22

  Compounds represented by Formula (I): 1 or a pharmaceutically acceptable salt thereof, are phosphodiesterrase 4 inhibitors useful in the treatment of asthma and inflammation.

  由化学式（I）表示的化合物： 1 或其药用可接受的盐，是磷酸二酯酶4抑制剂，用于治疗哮喘和炎症。
• [EN] RENIN INHIBITORS<br/>[FR] INHIBITEURS DE LA RÉNINE
  申请人：MERCK FROSST CANADA LTD

  公开号：WO2009070869A1

  公开（公告）日：2009-06-11

  The present invention relates to piperidinyl-based renin inhibitor compounds having the formula containing amino-terminal groups, and their use in treating cardiovascular events and renal insufficiency.

  本发明涉及含有氨基末端基团的哌啶基肾素抑制剂化合物，以及它们在治疗心血管事件和肾功能不全方面的用途。
• The Discovery of LML134, a Histamine H3 Receptor Inverse Agonist for the Clinical Treatment of Excessive Sleep Disorders
  作者：Thomas Troxler、Dominik Feuerbach、Xuechun Zhang、Charles R. Yang、Bharat Lagu、Mark Perrone、Tie‐Lin Wang、Karin Briner、Mark G. Bock、Yves P. Auberson

  DOI：10.1002/cmdc.201900176

  日期：2019.7.3

  Histamine H3 receptor (H3R) inverse agonists that have been in clinical trials for the treatment of excessive sleep disorders, have been plagued with insomnia as a mechanism‐based side effect. We focused on the identification of compounds that achieve high receptor occupancy within a short time, followed by rapid disengagement from the receptor, a target profile that could provide therapeutic benefits

  在临床试验中用于治疗过度睡眠障碍的组胺H3受体（H3R）反向激动剂已因失眠而困扰，这是一种基于机制的副作用。我们专注于鉴定可在短时间内实现高受体占有率，然后迅速与受体脱离的目标化合物，该目标谱可提供治疗益处而不会出现失眠的不良副作用。本文介绍了导致发现1-（1-甲基-6-氧代-1,6-二氢哒嗪-3-基）哌啶-4-基4-环丁基哌嗪-1-羧酸酯的优化工作（18 b，LML134 ）。